NCT06358391Completed
To Compare and Evaluate the Efficacy and Safety Between TS-RF System and BRK Transseptal Needles Used for Transseptal Puncture for Left Atrial Access.
A Prospective, Multi-center, Randomized, Single-blind, Non-inferiority Confirmatory Study Designed to Compare and Assess Efficacy and Safety Between "TS-RF System Consisting of a Electrosurgical System, General-purpose (TS-RF Generator) and a Electrosurgical System Electrode, Hand-controlled, General-purpose, Single-use (TS-RF Needle)" and "Needle, Puncture, Single-use (BRK Transseptal Needle)", Both of Which Are Used for the Transseptal Puncture Performed to Enable Left Atrial Access for the Treatment of Symptomatic Arrhythmia and Mitral Stenosis
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to compare and assess efficacy and safety between the study device "TS-RF system consisting of a electrosurgical system, general-purpose (TS-RF Generator) and a electrosurgical system electrode, hand-controlled, general-purpose, single-use (TS-RF Needle)" and the control device "needle, puncture, single-use (BRK Transseptal needle)", both of which are used for the transseptal puncture performed to enable left atrial access for the treatment of symptomatic arrhythmia and mitral stenosis and then to demonstrate that the study device is non-inferior to the control device.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 70 (actual)
- First submitted
- 1 Apr 2024
- Start date
- 21 Aug 2024
- Primary completion date
- 13 Oct 2026
- Lead sponsor
- Starmed
- Diseases
- Atrial fibrillation
- NCT number
- NCT06358391
What you commit to
- Study type: Interventional
- Participants enrolled: 70
- From 21 Aug 2024 to the primary completion date, 13 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Atrial fibrillation to reversible causes (e.g. hyperthyroidism, thoracic surgery)
- Currently participating or anticipated to participate in any other clinical trial of a drug, device or biologic that has the potential to interfere with the results of this study
Other illness
- \[For symptomatic arrhythmia and mitral stenosis\] If any of the following applies, you cannot participate in this clinical trial.1,26,37,45,46
- Patients with significant congenital heart defects, such as atrial septal defect or pulmonary vein (PV) abnormalities (excluding patent foramen ovale (PFO)).
- Unstable angina.
- liver disease (including active hepatitis) and kidney disease.
- Malignant tumors or hematological diseases or life expectancy of less than one (1) year.
Other
- Thrombus in the left atrium
- Known or suspected left atrial myxoma.
- Pre-existing hemidiaphragmatic paralysis
- Contraindication to anticoagulation or radiocontrast materials
- Cerebral ischemic event (strokes or TIAs) during the six-month interval preceding the consent date
- Unwilling or unable to comply fully with study procedures and follow-up
- A pregnant woman, a woman planning on becoming pregnant, or a lactating woman.
- Ineligible for study participation in the judgment of the investigator.
Who the study is looking for
- ≥ 18 years of age
- Diagnosed with one of the following cardiac disorders as shown in the medical record:
- \[Symptomatic arrhythmia\]
- "Atrial fibrillation" diagnostics (including paroxysmal, persistent, long-standing persistent and permanent atrial fibrillation)
- Diagnostic criteria: atrial fibrillation lasting ≥ 30 seconds as a result of standard 12-lead electrocardiogram (ECG) or single-lead ECG
- ECG feature: irregular R-R interval, lack of visible P waves, irregular atrial activation
- Symptoms: fatigue, palpitation, dyspnea, chest discomfort, sleep disorders, mental stress
- Type:
- Paroxysmal atrial fibrillation (stopping within 48 hours without any treatment; restoring the sinus rhythm with cardioversion within 7 days)
- Persistent atrial fibrillation (persisting for ≥ 7 days; including sinus rhythm restoration with direct-current cardioversion (DCC) or pharmacological cardioversion after the persistence)
- Long-standing persistent atrial fibrillation (persisting for ≥ 1 year; including cases requiring cardioversion)
- Permanent atrial fibrillation (The patient and healthcare provider accept atrial fibrillation and do not consider cardioversion; if cardioversion is considered, the atrial fibrillation is reclassified as long-standing persistent atrial fibrillation)
- "Paroxysmal Supraventricular Tachycardia" diagnostics
- = Clinical feature: The heart beats regularly 150 to 200 times per minute; the start and end of paroxysmal supraventricular tachycardia are clearly recognizable; these occur unexpectedly and stop abruptly.
- "Ectopic Atrial Rhythm Tachycardia" diagnostics
- = Clinical feature: Heart rhythm of less than 250 beats per minute; morphologic difference from P waves in the sinus rhythm; P waves that precede QRS waves are identifiable.
- "Ventricular Tachycardia" diagnostics = Clinical feature: Wide QRS waves appear in succession with a rapid ventricular rate of ≥ 100 beats per minute; the patients is diagnosed with persistent ventricular tachycardia if tachycardia persists for ≥ 30 seconds but with non-persistent ventricular tachycardia if not applicable.
- "Arrhythmia requiring left atrial access, including left atrial appendage occlusion, in the left atrium" diagnostics = Clinical feature: moderate or higher risk of stroke, risk of bleeding, or contraindication to anticoagulation therapy
- \[Symptomatic mitral stenosis\]
- -"Mitral Stenosis requiring percutaneous mitral valvuloplasty through left atrial access" diagnostics
- Diagnostic criteria: confirmation of mitral stenosis with echocardiography and assessment of severity
- Symptoms: dyspnea; shortness of breath even at rest or inability to sleep in a supine position if dyspnea worsens; may accompanied by coughing, sputum, and chest pain.
- Understood this clinical study and voluntarily signed the informed consent form (ICF)1
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bucheon Sejong Hospital Coordinator of this site? Confirm its status | Bucheon-si | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.